Cargando…
Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
SIMPLE SUMMARY: The breakthrough in developing novel HER2-targeting antibody drug conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically revolutionize the clinical treatment landscape of HER2 negative breast cancers, as well as the pathologic evaluation of HER...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817919/ https://www.ncbi.nlm.nih.gov/pubmed/36612123 http://dx.doi.org/10.3390/cancers15010126 |